Search Results

Palatin Technologies, Inc. today announced that it has entered into a warrant inducement agreement with an institutional investor to exercise certain outstanding warrants that the Company issued in November 2022 and October 2023 totaling 3,233,277 shares of the Company’s common stock for gross proceeds of approximately $6.1 million.

Purespring Therapeutics is presenting preclinical data at the 61st European Renal Association Congress, showing that transgenes can be efficiently targeted to podocytes to replace defective genes or to use the podocyte as a protein factory to modulate kidney biology.

Fresenius Medical Care today announced the presentation of nearly 40 company-affiliated research abstracts at the 61st European Renal Association (ERA) Congress, taking place May 23-26, 2024, in Stockholm, Sweden and virtually.

According to the Vision Research Reports, the global epigenetics market size was estimated at around USD 14.65 billion in 2023 and it is forecasted to be worth over USD 61.04 billion by 2033 with a CAGR of 15.34% from 2024 to 2033

According to recent study by nova one advisor, the U.S. tissue diagnostics market size was exhibited at USD 2.46 billion in 2023 and is projected to hit around USD 3.61 billion by 2033, growing at a CAGR of 3.92 % during the forecast period 2024 to 2033.

According to Vision Research Reports, the global cancer biomarkers market size was accounted for USD 15.68 billion in 2023 and it is increasing around USD 61.37 billion by 2033 with a CAGR of 14.62% from 2024 to 2033.

Vera Therapeutics, Inc. today announced two presentations of data from the Phase 2b ORIGIN clinical trial of atacicept for the treatment of IgA nephropathy (IgAN) will be made at the 61st European Renal Association Congress (ERA24), which is taking place May 23—26, 2024, both virtually and in Stockholm.

RenovoRx, Inc. today announced that it has closed a private placement (the “private placement” or the “financing”) resulting in gross proceeds of approximately $6.1 million, before deducting offering expenses.